Katalóg evidencie publikačnej činnosti PU

ID záznamu:PU.Prešov.2017022511545634
Autor:Abrams Paul H. (10%)
Autor:Kelleher Con J. (10%)
Autor:Staskin David R. (10%)
Autor:Kay Richard (10%)
Autor:Martan Alois (10%)
Autor:Minčík Ivan (20%)
Autor:Newgreen Donald T. (10%)
Autor:Ridder Arwin M. (10%)
Autor:Paireddy Asha (5%)
Autor:Van Maanen Rob (5%)
Názov:Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY)
Zdroj:World journal of urology
Lokácia:Vol. 35, no. 5 (2017), s. 827-838
Ohlas:[1] CHAPPLE, Ch.R., CRUZ, F., CARDOZO, L. et al. 2020. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebomedical clinics of North America. In European urology, ISSN 0302-2838. 2020, vol. 77, no. 1, s. 119-128.
Ohlas:[1] MANUELYAN, Z., MUNIZ, K.S., STEIN, E. 2020. Common urinary and bowel disorders in the geriatric population. In Medical clinics of North America, ISSN 0025-7125. 2020, vol. 104, no. 5, s. 827-842.
Ohlas:[1] GRATZKE, Ch., CHAPPLE, Ch., MUELLER, E.R. et al. 2019. Efficacy and safety of combination pharmacotherapy for patients with overactive bladder: a rapid evidence assessment. In European urology, ISSN 0320-2838. 2019, vol. 76, no. 6, 767-779.
Ohlas:[1] EL-ZAWAHRY, A., RIZK, D.E.E. 2020. Combination pharmacotherapy for the treatment of the overactive bladder syndrome: a new solution for an old problem?. In International urogynecology journal, ISSN 0937-3462. 2020, vol. 31, no. 5, s. 855-856.
Ohlas:[1] WIEDEMANN, A., BECHER, K., BOJACK, B. et al. 2019. Urinary incontinence in geriatric patients: pharmacological therapy. In Aktuelle urologie, ISSN 0001-7868. 2019, vol. 50, no. 4, s. 424-440.
Ohlas:[1] IGAWA, Y., AIZAWA, N., MICHEL, M.C. 2019. beta(3)-Adrenoceptors in the normal and diseased urinary bladder-What are the open questions?. In British journal of pharmacology, ISSN 0007-1188. 2019, vol. 176, no. 14, suppl. s. 2525-2538.
Ohlas:[1] EL-ZAWAHRY, Ahmed 2019. Combination pharmacotherapy for treatment of overactive bladder (OAB). In Current urology reports, ISSN 1527-2737. 2019, vol. 20, no. 6, srt. no. 33.
Ohlas:[1] JOHNSTON, K.M., WALKER, D., LAKZADEH, P. 2019. Characterizing the health-related quality of life burden of overactive bladder using disease-specific patient-reported outcome measures: a systematic literature review. In Advances in therapy, ISSN 0741-238X. 2019, vol. 33, no. 3, s. 548-562.
Ohlas:[1] SERATI, M., ANDERSSON, K.-E., DMOCHOWSKI, R. et al. 2019. Systematic review of combination drug therapy for non-neurogenic: lower urinary tract symptoms. In European urology, ISSN 0302-2838. 2019, vol. 75, no. 1, s. 129-168.
Ohlas:[1] KUO, Hann-Chorng 2018. Individualizing medical treatment of overactive bladder. In Tzu Chi medical journal, ISSN 1016-3190. 2018, vol. 30, no. 4, s. 195-199.
Ohlas:[1] ROVNER, E.S., RAYMOND, K., ANDRUCZYK, E. et al. 2018. Low-dose desmopressin and tolterodine combination therapy for treating nocturia in women with overactive bladder: A double-blind, randomized, controlled study. In LUTS: Lower urinary tract symptoms, ISSN 1757-5664. 2018, vol. 10, no. 3, s. 221-230.
Ohlas:[1] XU, Y., LIU, R., LIU, Ch. et al. 2017. Meta-analysis of the efficacy and safety of mirabegron add-on therapy to solifenacin for overactive bladder. In International neurourology journal, ISSN 2093-4777. 2017, vol. 21, no. 3, s. 212-219.
Ohlas:[1] SERATI, M., MAGGIORE, L.R., SORICE, P. et al. 2017. Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?. In International urogynecology journal, ISSN 0937-3462. 2017, vol. 28, no. 7, s. 1033-1039.
Ohlas:[1] KUNG, Y.-M., HSU, W.-H., WU, M.-C. et al. 2017. Recent advances in the pharmacological management of gastroesophageal reflux disease. In Digestive diseases and sciences, ISSN 0163-2116. 2017, vol. 62, no. 12, s. 3298-3316.
Ohlas:[1] CORCOS, J., PRZYDACZ, M., CAMPEAU, L. et al. 2017. CUA guideline on adult overactive bladder. In Canadian urological association journal, ISSN 1920-1214. 2017, vol. 11, no. 5, s. 142-173.
Ohlas:[1] ROBINSON, D., KELLEHER, C., STASKIN, D. et al. 2018. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. In Neurology and urodynamics, ISSN 0733-2467. 2018, vol. 37, no. 1, s. 394-406.
Ohlas:[1] SHAH, D.A., TAHILRAMANI, P.J., PATEL, V.B. et al. 2019. High-performance thin-layer chromatographic method for the estimation of mirabegron and solifenacin succinate used in the treatment of overactive bladder syndrome. In Journal of planar chromatography - modern TLC, ISSN 0933-4173. 2019, vol. 32, no. 4, s. 323-327.
Ohlas:[1] ANDERSSON, K.-E., MADERSBACHER, H., ALTAWEEL, W. et al. 2019. Drug treatment. In Neurology: theory and practice. Netherlands : Springer, 2019, s. 231-259. ISBN 978-940177509.
Ohlas:[1] CARLSON, K.V., ROVNER, E.S., NAIR, K.V. et al. 2019. Factors associated with improvements in patient-reported outcomes during mirabegron or antimuscarinic treatment of overactive bladder syndrome: A registry study (PERSPECTIVE). In Advances in therapy, ISSN 0741-238X. 2019, vol. 36, no. 8, s. 1906-1921.
Ohlas:[1] BURTSCHER, T., BEKTIC, J. 2019. BPO/LUTS—latest news on drug treatment. In Journal fur urologie und urogynakologie, ISSN 1023-6090. 2019, vol. 26, no. 4, s. 114-120.